AIC
VRTX icon

Archer Investment Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

Archer Investment Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Buy
46
+7
+18% +$3.1K ﹤0.01% 655
2026
Q1 		$17.4K Sell
39
-35
-47% -$16.3K ﹤0.01% 700
2025
Q4 		$33.5K Buy
74
+35
+90% +$15.1K 0.01% 531
2025
Q3 		$15.3K Hold
39
– – ﹤0.01% 654
2025
Q2 		$17.4K Hold
39
– – ﹤0.01% 624
2025
Q1 		$18.9K Buy
39
+3
+8% +$1.4K ﹤0.01% 593
2024
Q4 		$14.5K Hold
36
– – ﹤0.01% 632
2024
Q3 		$16.7K Hold
36
– – ﹤0.01% 605
2024
Q2 		$16.9K Hold
36
– – ﹤0.01% 579
2024
Q1 		$15K Hold
36
– – ﹤0.01% 582
2023
Q4 		$14.6K Hold
36
– – ﹤0.01% 588
2023
Q3 		$12.5K Hold
36
– – ﹤0.01% 583
2023
Q2 		$12.7K Buy
+36
New +$12.1K ﹤0.01% 577
2019
Q4 		– Sell
-30
Closed -$5K – 641
2019
Q3 		$5K Buy
+30
New +$5.31K ﹤0.01% 400

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Archer Investment Corporation's VRTX Position: Q2 2026 in Review

Archer Investment Corporation increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, buying an estimated $3.1K and bringing the position to 46 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

Archer Investment Corporation first reported a position in VRTX in Q3 2019 and has held it in 14 quarters since. The position peaked at $33.5K in Q4 2025. 1,296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Archer Investment Corporation held 46 shares of Vertex Pharmaceuticals worth $22.9K as of Q2 2026.
  • Archer Investment Corporation bought 7 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.1K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Archer Investment Corporation's portfolio in Q2 2026, its #655 holding.
  • Archer Investment Corporation first reported a position in Vertex Pharmaceuticals in Q3 2019 and has held it in 14 quarters since.
  • Archer Investment Corporation's Vertex Pharmaceuticals position peaked at $33.5K in Q4 2025.
  • 1,296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Archer Investment Corporation's 13F filing for Q2 2026, filed 3 Aug 2026.